Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995634 | 1.00 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL5733485 | 0.87 | PTGER4 (0.48) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL5733480 | 0.87 | PTGER4 (0.48) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL10969201 | 0.84 | PTGER4 (0.47) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL6712960 | 0.82 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL6712964 | 0.82 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL4994022 | 0.82 | PTGER4 (0.47) | PTGER4PTGER3PTGER2USP2ALDH1A1 | |
| SCHEMBL4994025 | 0.82 | PTGER4 (0.47) | PTGER4PTGER3PTGER2USP2ALDH1A1 | |
| SCHEMBL10970283 | 0.81 | PTGER4 (0.62) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL18831938 | 0.81 | PTGER4 (0.62) | PTGER4PTGER3PTGER2KCNH2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2005027931-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AN EP2 OR EP4 SELECTIVE AGONIST | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | PFIZER INC | 2005-03-24 | — | — | US | disclosed |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| WO-2003008377-A1 | PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | VDR, CYP24A1, CYP2R1 | PTGER4 5/4885PTGER3 7/4885PTGER2 4/4885 |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | PTGER4 1/4885PTGER3 11/4885PTGER2 15/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.